15 minutes delayed
Comments
Loading...
DECIPHERA PHARMACEUTICALS INC COM
DCPHNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
DECIPHERA PHARMACEUTICALS INC COM (NASDAQ:DCPH) Stock, Analyst Ratings, Price Targets, Forecasts
Quote.Descriptions.analyst-ratings.
Analyst Firms Making Recommendations1
Barclays
JonesTrading
Jefferies
JP Morgan
Stifel
1calculated from analyst ratings
Analyst Ratings for DECIPHERA PHARMACEUTICALS INC COM
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/30/2024 | Buy Now | — | Guggenheim | Michael Schmidt | — | Downgrade | Buy → Neutral | Get Alert |
| 04/30/2024 | Buy Now | — | JMP Securities | Reni Benjamin | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 04/30/2024 | Buy Now | — | Barclays | Peter Lawson | $9 → $26 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 04/29/2024 | Buy Now | — | JonesTrading | Soumit Roy | → $25.6 | Downgrade | Buy → Hold | Get Alert |
| 04/29/2024 | Buy Now | — | Jefferies | Eun Yang | $26 → $25.6 | Downgrade | Buy → Hold | Get Alert |
| 03/20/2024 | Buy Now | — | JP Morgan | Jessica Fye | $14 → $16 | Maintains | Neutral | Get Alert |
| 02/07/2024 | Buy Now | — | Stifel | Bradley Canino | $22 → $23 | Maintains | Buy | Get Alert |
| 11/20/2023 | Buy Now | — | JP Morgan | Jessica Fye | → $14 | Reinstates | → Neutral | Get Alert |
| 10/31/2023 | Buy Now | — | Stifel | Bradley Canino | $20 → $22 | Maintains | Buy | Get Alert |
| 10/31/2023 | Buy Now | — | HC Wainwright & Co. | Andrew Fein | $25 → $30 | Maintains | Buy | Get Alert |
| 10/31/2023 | Buy Now | — | JonesTrading | Soumit Roy | — | Upgrade | Hold → Buy | Get Alert |
| 10/30/2023 | Buy Now | — | Piper Sandler | Christopher Raymond | $18 → $23 | Upgrade | Neutral → Overweight | Get Alert |
| 08/10/2023 | Buy Now | — | HC Wainwright & Co. | Andrew Fein | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/10/2023 | Buy Now | — | Stifel | Bradley Canino | $14 → $20 | Upgrade | Hold → Buy | Get Alert |
| 06/05/2023 | Buy Now | — | JMP Securities | Reni Benjamin | → $23 | Reiterates | → Market Outperform | Get Alert |
| 05/04/2023 | Buy Now | — | JMP Securities | Reni Benjamin | → $23 | Reiterates | → Market Outperform | Get Alert |
| 03/15/2023 | Buy Now | — | JMP Securities | Reni Benjamin | → $23 | Reiterates | → Market Outperform | Get Alert |
| 02/08/2023 | Buy Now | — | HC Wainwright & Co. | Andrew Fein | → $25 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | — | SVB Leerink | Andrew Berens | → $30 | Reiterates | → Outperform | Get Alert |
| 02/07/2023 | Buy Now | — | SVB Leerink | Andrew Berens | $28 → $30 | Maintains | Outperform | Get Alert |
| 01/25/2023 | Buy Now | — | Cowen & Co. | Tyler Van Buren | $25 → $30 | Maintains | Outperform | Get Alert |
| 01/06/2023 | Buy Now | — | JonesTrading | Soumit Roy | — | Upgrade | Sell → Hold | Get Alert |
| 01/04/2023 | Buy Now | — | SVB Leerink | Andrew Berens | $25 → $28 | Maintains | Outperform | Get Alert |
| 01/04/2023 | Buy Now | — | Barclays | Peter Lawson | $8 → $9 | Maintains | Underweight | Get Alert |
| 01/04/2023 | Buy Now | — | Guggenheim | Michael Schmidt | → $22 | Upgrade | Neutral → Buy | Get Alert |
| 09/27/2022 | Buy Now | — | Stifel | Bradley Canino | $11 → $18 | Maintains | Hold | Get Alert |
| 09/12/2022 | Buy Now | — | SVB Leerink | Andrew Berens | $21 → $25 | Maintains | Outperform | Get Alert |
| 09/12/2022 | Buy Now | — | HC Wainwright & Co. | Andrew Fein | $20 → $25 | Maintains | Buy | Get Alert |
| 08/29/2022 | Buy Now | — | Cowen & Co. | Tyler Van Buren | → $25 | Initiates | → Outperform | Get Alert |
| 08/05/2022 | Buy Now | — | SVB Leerink | Andrew Berens | $15 → $21 | Maintains | Outperform | Get Alert |
| 08/05/2022 | Buy Now | — | HC Wainwright & Co. | Andrew Fein | $15 → $20 | Maintains | Buy | Get Alert |
| 08/05/2022 | Buy Now | — | JMP Securities | Reni Benjamin | → $23 | Upgrade | Market Perform → Market Outperform | Get Alert |
| 02/28/2022 | Buy Now | — | Barclays | Peter Lawson | $11 → $6 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 12/01/2021 | Buy Now | — | HC Wainwright & Co. | Andrew Fein | — | Maintains | Buy | Get Alert |
| 11/08/2021 | Buy Now | — | Truist Securities | Robyn Karnauskas | — | Downgrade | Buy → Hold | Get Alert |
| 11/08/2021 | Buy Now | — | Canaccord Genuity | Arlinda Lee | — | Downgrade | Buy → Hold | Get Alert |
| 11/08/2021 | Buy Now | — | HC Wainwright & Co. | Andrew Fein | — | Maintains | Buy | Get Alert |
| 11/08/2021 | Buy Now | — | Barclays | Peter Lawson | — | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/08/2021 | Buy Now | — | Stifel | Bradley Canino | — | Downgrade | Buy → Hold | Get Alert |
| 11/05/2021 | Buy Now | — | Truist Securities | Robyn Karnauskas | — | Downgrade | Buy → Hold | Get Alert |
| 11/05/2021 | Buy Now | — | JMP Securities | Reni Benjamin | — | Maintains | Market Outperform | Get Alert |
| 08/04/2021 | Buy Now | — | HC Wainwright & Co. | Andrew Fein | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for DECIPHERA PHARMACEUTICALS INC COM (DCPH) stock?
The latest price target for DECIPHERA PHARMACEUTICALS INC COM (NASDAQ:DCPH) was reported by Guggenheim on April 30, 2024. The analyst firm set a price target for $0.00 expecting DCPH to fall to within 12 months (a possible NaN% downside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for DECIPHERA PHARMACEUTICALS INC COM (DCPH)?
The latest analyst rating for DECIPHERA PHARMACEUTICALS INC COM (NASDAQ:DCPH) was provided by Guggenheim, and DECIPHERA PHARMACEUTICALS INC COM downgraded their neutral rating.
When was the last upgrade for DECIPHERA PHARMACEUTICALS INC COM (DCPH)?
The last upgrade for DECIPHERA PHARMACEUTICALS INC COM happened on April 30, 2024 when Barclays raised their price target to $26. Barclays previously had an underweight for DECIPHERA PHARMACEUTICALS INC COM.
When was the last downgrade for DECIPHERA PHARMACEUTICALS INC COM (DCPH)?
The last downgrade for DECIPHERA PHARMACEUTICALS INC COM happened on April 30, 2024 when Guggenheim changed their price target from N/A to N/A for DECIPHERA PHARMACEUTICALS INC COM.
When is the next analyst rating going to be posted or updated for DECIPHERA PHARMACEUTICALS INC COM (DCPH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of DECIPHERA PHARMACEUTICALS INC COM, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for DECIPHERA PHARMACEUTICALS INC COM was filed on April 30, 2024 so you should expect the next rating to be made available sometime around April 30, 2025.
Is the Analyst Rating DECIPHERA PHARMACEUTICALS INC COM (DCPH) correct?
While ratings are subjective and will change, the latest DECIPHERA PHARMACEUTICALS INC COM (DCPH) rating was a downgraded with a price target of $0.00 to $0.00. The current price DECIPHERA PHARMACEUTICALS INC COM (DCPH) is trading at is $undefined, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.